Diffuse large B cell lymphoma laboratory tests: Difference between revisions

	Diffuse large B cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Diagnosis
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Diffuse large B cell lymphoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Diffuse large B cell lymphoma laboratory tests
CDC on Diffuse large B cell lymphoma laboratory tests
Diffuse large B cell lymphoma laboratory tests in the news
Blogs on Diffuse large B cell lymphoma laboratory tests
Directions to Hospitals Treating Diffuse large B cell lymphoma
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests

Revision as of 13:26, 26 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Laboratory tests helpful in the diagnosis of diffuse large B cell lymphoma include complete blood count, LDH, and lymph node biopsy

Laboratory studies include^[1]

Pregnancy test among female patients who are planned to undergo chemotherapy
Hepatitis B testing prior to initiation of treatment among patients who either receive anti-CD20 monoclonal antibody-based regimens or patients with at least one risk factor
Hepatitis C among high-risk patients

@@ Line 9: / Line 9: @@
 * Serum lactate dehydrogenase (LDH)
 * [[Comprehensive metabolic panel]]
-* Lymph node or extranodal tissue biopsy
+* Immunohistological panel
-* CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
+::*''Essential'': CD3, CD5, CD10, CD20, BCL2, BCL6, and IRF4/MUM1
-* [[MUGA scan]] or [[echocardiograms]] are recommended when anthracyclines and anthracenedione containing regimens are used
+::*''May be additionally required'': Ki-67, CD43, CD21, and CD23
-* [[Bone marrow biopsy]] with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
+* Pregnancy test among female patients who are planned to undergo chemotherapy
-* Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
+* Hepatitis B testing prior to initiation of treatment among patients who either receive anti-CD20 monoclonal antibody-based regimens or patients with at least one risk factor
-* Hepatitis C testing is needed in high-risk patients
+* Hepatitis C among high-risk patients
 ==References==